Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8026594 | 0.89 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL16409736 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL18002248 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL29043345 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL10087553 | 0.84 | HTT (0.67) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL13055383 | 0.84 | LMNA (0.80) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL15289516 | 0.83 | LMNA (0.57) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL11930103 | 0.82 | HTT (0.65) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL21251567 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL15202883 | 0.82 | SYK (0.64) | SMN1; SMN2LMNAHTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619037-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024105197-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | VINCERX PHARMA GMBH (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-9315498-B2 | Arlethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315498-B2 | Arlethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315498-B2 | Arlethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| CN-103857668-B | As the ethynyl derivatives serving of MGLUR5 allosteric modulators | HOFFMAN-LA ROCHE LTD. (CH) | 2016-04-13 | — | — | CN | disclosed |
| EP-2558457-B1 | ARYLETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2558457-B1 | ARYLETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2763977-B1 | ETHYNYL DERIVATIVES AS MGLUR5 ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-02-24 | — | — | EP | disclosed |
| EP-2763977-B1 | ETHYNYL DERIVATIVES AS MGLUR5 ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-02-24 | — | — | EP | disclosed |
| US-20130090332-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050454-A1 | ETHYNYL DERIVATIVES AS MGLUR5 ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090332-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050454-A1 | ETHYNYL DERIVATIVES AS MGLUR5 ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| EP-2558457-A1 | ARYLETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011128279-A1 | ARYLETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128279-A1 | ARYLETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251169-A1 | Arylethynyl derivatives | HOFFMANN-LA ROCHE, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110251169-A1 | Arylethynyl derivatives | HOFFMANN-LA ROCHE, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110251169-A1 | Arylethynyl derivatives | HOFFMANN-LA ROCHE, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090332-A1 | ETHYNYL DERIVATIVES | GRM5, GRIK5, GRM1 | SMN1; SMN2 3479/4885LMNA 4719/4885HTT 1835/4885 |
| US-20110251169-A1 | Arylethynyl derivatives | GRM5, GRM1, GRM3 | SMN1; SMN2 3190/4885LMNA 4558/4885HTT 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.